By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

June is Men’s Health Month, so it seems appropriate to begin the month by focusing on a topic specific to men’s wellness and ...

By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...

Data from the PROTEUS trial showed that adding a hormone-blocking pill called apalutamide to standard hormone therapy, both ...

Every two minutes, a man in the U.S. is diagnosed with prostate cancer. Every 15 minutes, another dies of it. Prostate cancer disproportionately affects Black men. In D.C., more die from prostate ...

Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We ...

Risk factors are things that raise your chances of getting a disease. For each person, there’s a mix of genetic, biological and lifestyle factors that play a part in prostate cancer risk. About 1 in ...

Talazoparib plus enzalutamide reduces progression risk by 50% in men with DNA repair alter ...

The UK's National Screening Committee has recommended that only a very small group of men at high risk of prostate cancer ...

Only men with a dangerous genetic variant and a family history of cancer should be offered screening, say UK advisors.

Prostate cancer is the most commonly diagnosed cancer in the UK, with more than 63,000 new cases each year. Yet for many men, understanding their treatment options remains far from straightforward ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...